Platelet PAR-1 Activation in Health and Diabetes

Vanderbilt University Medical Center

Status: Completed

Conditions: Healthy; Type 2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT04280549

192207

Details and patient eligibility

About

Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.

Enrollment: 100 patients

Sex: All

Ages: 60+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men and women ≥60 years of age OR
• Type 2 diabetic men and women ≥60 years of age

Exclusion criteria

• Active cancer
• Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease
• Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR <30 cc/min).
• Pregnancy or lactation
• Active vasculitis
• Anticipated lifespan < 2 years
• Current use of a DOAC

Trial design

100 participants in 2 patient groups

Healthy Subjects

Description:

Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.

Type 2 Diabetic Subjects

Description:

Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.